Eaton Vance Worldwide Health Sciences Fund C (ECHSX)
13.26
+0.01
(+0.08%)
USD |
Nov 05 2025
Key Stats
Customize
| Net Expense Ratio | Total Assets Under Management | Weighted Average Dividend Yield | Turnover Ratio (Generic) |
|---|---|---|---|
| 1.92% | 833.53M | 1.60% | -- |
| 1 Year Fund Level Flows | 1 Year Total Returns (Daily) | Annualized Total Returns Since Inception (Daily) | Max Drawdown (Since Inception) |
| -139.96M | -5.07% | Upgrade | Upgrade |
Basic Info
| Investment Strategy | |
| The Fund seeks long-term capital growth by investing in a global, diversified portfolio of securities of health science companies. The Fund normally invests at least 80% of its assets in securities of companies primarily engaged in the discovery, development, production or distribution of products related to health care. |
| General | |
| Security Type | Mutual Fund |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Global Peer Group | Equity Sector Healthcare |
| Peer Group | Global Health/Biotechnology Funds |
| Global Macro | Equity Industry Sector |
| US Macro | World Sector Equity Funds |
| YCharts Categorization | -- |
| YCharts Benchmark | -- |
| Prospectus Objective | Global Health/Biotechnology Funds |
| Fund Owner Firm Name | Eaton Vance |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
Net Fund Flows Versus Peer Group
1 Month
% Rank:
67
-609.20M
Peer Group Low
625.87M
Peer Group High
1 Year
% Rank:
67
-139.96M
-7.211B
Peer Group Low
494.55M
Peer Group High
3 Months
% Rank:
67
-1.954B
Peer Group Low
680.53M
Peer Group High
3 Years
% Rank:
57
-14.49B
Peer Group Low
486.70M
Peer Group High
6 Months
% Rank:
67
-3.594B
Peer Group Low
531.84M
Peer Group High
5 Years
% Rank:
57
-21.89B
Peer Group Low
822.57M
Peer Group High
YTD
% Rank:
67
-5.395B
Peer Group Low
542.23M
Peer Group High
10 Years
% Rank:
77
-41.26B
Peer Group Low
765.68M
Peer Group High
Date Unavailable
Risk
Performance Versus Peer Group
Annual Total Returns Versus Peers
As of November 06, 2025.
Asset Allocation
As of August 31, 2025.
| Type | % Net |
|---|---|
| Cash | 0.05% |
| Stock | 99.64% |
| Bond | 0.05% |
| Convertible | 0.00% |
| Preferred | 0.00% |
| Other | 0.26% |
Top 10 Holdings
| Name | % Weight | Price | % Change |
|---|---|---|---|
| Eli Lilly & Co. | 10.18% | 925.81 | 2.09% |
| AbbVie, Inc. | 6.62% | 216.77 | 0.41% |
| AstraZeneca PLC | 6.09% | 165.26 | 0.00% |
| Roche Holding AG | 4.98% | 322.60 | -0.91% |
| Abbott Laboratories | 4.98% | 124.54 | -1.00% |
| Johnson & Johnson | 4.16% | 186.00 | -0.46% |
| Zoetis, Inc. | 3.45% | 120.49 | -3.19% |
| Novo Nordisk A/S | 3.43% | 49.25 | 2.60% |
| UnitedHealth Group, Inc. | 3.39% | 327.74 | -0.93% |
| Bristol Myers Squibb Co. | 3.19% | 46.47 | 1.93% |
Fees & Availability
| Fees | |
| Actual 12B-1 Fee | 1.00% |
| Actual Management Fee | 0.76% |
| Administration Fee | 38.72K% |
| Maximum Front Load | -- |
| Maximum Deferred Load | 1.00% |
| Maximum Redemption Fee | -- |
| General Availability | |
| Available for Insurance Product | -- |
| Available for RRSP | -- |
| Purchase Details | |
| Open to New Investors |
|
| Minimum Initial Investment | 1000.00 None |
| Minimum Subsequent Investment | 0.00 None |
Basic Info
| Investment Strategy | |
| The Fund seeks long-term capital growth by investing in a global, diversified portfolio of securities of health science companies. The Fund normally invests at least 80% of its assets in securities of companies primarily engaged in the discovery, development, production or distribution of products related to health care. |
| General | |
| Security Type | Mutual Fund |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Global Peer Group | Equity Sector Healthcare |
| Peer Group | Global Health/Biotechnology Funds |
| Global Macro | Equity Industry Sector |
| US Macro | World Sector Equity Funds |
| YCharts Categorization | -- |
| YCharts Benchmark | -- |
| Prospectus Objective | Global Health/Biotechnology Funds |
| Fund Owner Firm Name | Eaton Vance |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
Fundamentals
| General | |
| Distribution Yield | -- |
| Dividend Yield TTM (11-4-25) | 1.14% |
| 30-Day SEC Yield (12-31-24) | 21.19M% |
| 7-Day SEC Yield | -- |
| Number of Holdings | 44 |
| Stock | |
| Weighted Average PE Ratio | 33.93 |
| Weighted Average Price to Sales Ratio | 6.574 |
| Weighted Average Price to Book Ratio | 9.805 |
| Weighted Median ROE | 37.47% |
| Weighted Median ROA | 10.82% |
| ROI (TTM) | 15.87% |
| Return on Investment (TTM) | 15.87% |
| Earning Yield | 0.0369 |
| LT Debt / Shareholders Equity | 2.098 |
| Number of Equity Holdings | 42 |
As of August 31, 2025
Growth Metrics
| EPS Growth (1Y) | 15.42% |
| EPS Growth (3Y) | 11.60% |
| EPS Growth (5Y) | 11.33% |
| Sales Growth (1Y) | 12.63% |
| Sales Growth (3Y) | 9.05% |
| Sales Growth (5Y) | 11.51% |
| Sales per Share Growth (1Y) | 13.12% |
| Sales per Share Growth (3Y) | 9.42% |
| Operating Cash Flow - Growth Rate (3Y) | 5.60% |
As of August 31, 2025
Fund Details
Top Portfolio Holders
| Name | % Weight |
|---|---|
| Portfolio A | 5.00% |
| Portfolio B | 3.50% |
| Portfolio C | 2.25% |
Excel Add-In Codes
| Name: =YCI("M:ECHSX", "name") |
| Broad Asset Class: =YCI("M:ECHSX", "broad_asset_class") |
| Broad Category: =YCI("M:ECHSX", "broad_category_group") |
| Prospectus Objective: =YCI("M:ECHSX", "prospectus_objective") |
| To find the codes for any of our securities and financial metrics, see our Complete Excel Reference. |